🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Looking forward to presenting prelim results of our phase 1 study of intravesical Fc-engineered anti-CD40 agonistic antibody in NMIBC at AACR. Amazing MSK/RU collaboration led by @bbmdms Jonathan Rosenberg MD moving from the bench to the clinic! #AACR24 abstractsonline.com/pp8/#!/20272/p…

Schmitt, Duval, Girard et al @IpbsToulouse show TL1A is an epithelial cytokine that cooperates w/ IL-33 in the initiation of allergic airway #inflammation. TL1A functions as an alarmin important for early induction of IL-9high ILC2s after allergen exposure hubs.la/Q02sqCPg0

Anyone still think we should not be using immune checkpoint inhibitors before surgery? Or that use of adjuvant ICI only is as good as neoadjuvant ICI? Phase 3 trial in resectable melanoma now in NEJM concurrent with plenary by Christian Blank #ASCO24 nejm.org/doi/full/10.10…

Final results of #CORE001 trial out now Nature Medicine (1/14) 35 pts with BCG-UR CIS treated w/ Creto + pembro 👉12mo CR (per RBB) = 57.1% (ITT) 👉24mo CR = 54% *(Auth Corr) 👉No patient progressed to MIBC 👉No synergistic toxicity Gary Steinberg nature.com/articles/s4159…

We are wrapping up our BC^3 series with a special keynote from Dr. Wolf Fridman on Wednesday, June 26th at 11 AM EST. Join us for this dynamic lecture! #TLS Daniel Hollern

Results from our Phase 1 clinical trial on the combination of botensilimab and balstilimab for MSS mCRC have been published in Nature Medicine. Read the full publication here: go.nature.com/4enyRla

Pleased to share our recent work on the interplay of obesity and IO responses in endometrial cancer at @jclinicalinves. Nicolás Gómez Banoy did a fantastic job leading this work. Thanks to Paul Cohen and the MSKCC Team Uterus supporting this. 3 🇨🇴 here! See 🧵 below! jci.org/articles/view/…

To improve agonist CD40 Abs for clinical use, Osorio, Knorr, Weitzenfeld, et al. evaluated 2141-V11, an Fc-engineered anti-CD40 (with optimized FcγRIIB binding) in a phase 1 study (12 patients). bit.ly/4cJhCcg  Rockefeller University

Grateful and honored that our project on the therapeutic targeting of regulatory T cells (Tregs) was selected by Bladder Cancer Advocacy Network 🙏🏻 Let’s deplete these Tregs ! Rockefeller University

How do T cells reach melanoma brain tumors? Using in vivo microscopy, we discovered a new route for T cells to enter the brain via distinct peri-tumoral venous vessels. Our newest paper is now online Immunity. authors.elsevier.com/sd/article/S10… A 🧵👇

Plz check out our new paper on pre-op SRS and the immune microenvironment of human brain metastases. nature.com/articles/s4146… Big team effort: Carey Jansen, MD PhD Meghana Pagadala MD PhD Haydn Kissick Maria Andrea Cardenas Mohammad K. Khan, MD and many more.

Check out our latest paper “Differentiation fate of a stem-like CD4 T cell control immunity to cancer”, led by Maria Andrea Cardenas now live nature tinyurl.com/33d24k89 . This work examines how CD4 T cell differentiation dictates the outcome of the cancer response. Thread below

Just published📢 Our new forum article on Fc-optimized checkpoint antibodies for cancer therapy. New to immunotherapy and antibody engineering? This one’s for you! Co-authored with Alan Korman. Trends in Molecular Medicine #CancerImmunotherapy #FcEngineering sciencedirect.com/science/articl…

Long awaited practice-changing results from ph 3 CM8HW now out in The Lancet. Nivo/ipi sign better than nivo mono in dMMR mCRC Sara Lonardi Bristol Myers Squibb #GI25 thelancet.com/journals/lance…

Very excited to see this in print! Such promising outcomes for immune cold #sarcomas with Botensilimab Plus Balstilimab ascopubs.org/doi/10.1200/JC… Agenus CU Cancer Center

🚨 PLEASE SHARE! Early-career bladder cancer researchers: Apply now for BCAN's 2025 Young Investigator Awards! $75K in funding, mentorship, and networking opportunities await. Advance your research and career. 🧬 Deadline: Feb 21, 2025. Click for info: bcan.org/bcan-research/…